QAI Labs

United StatesProtein designSugar Land, Texas, United StatesPrivate

NOVA-3 assembles multi-specific antibodies from a curated library of antibody parts and ranks the combinations in software before lab tests, with quantum-chemistry steps run on classical simulators; it holds two in-licensed antibody programmes, both early preclinical.

Disclosed total-

Rounds on record1

Latest round$5M in Quanome shares, a value the parties assignedStrategic investment, share swap (signed, not yet closed) · 2026-11-09

Last stated valuation$100Mstated by SEC filing

Investors named1

Research on recordNone yet

Money and evidence

Closed round

No research by this company is on the record yet.

Rounds and research, on one timeline

2026-11-09Strategic investment, share swap (signed, not yet closed)
Round
$5M in Quanome shares, a value the parties assigned$100M · stated by SEC filing
For: accelerate the evaluation and continued development of NOVA-3; after closing the two intend a strategic collaboration in AI drug discovery
Models and platform
Quanome's 8-K of 9 November and its press release: QAI Labs issues 31,579 new shares (about 5%) for 6,541,236 new Quanome shares (about 19% of Quanome's stock before the issue). The agreement was signed on 4 November and lapses if not closed by 31 December 2026. No cash changes hands; the $5M and the implied $100M come from the value the parties assigned to the Quanome shares.
Quanome Technologies
On the deal: Yang Li (Chief Executive Officer; spoke for the investor in the announcement, Quanome Technologies)
Stated in a filing · sec.gov ↗On the timeline →

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →